Gilead Sciences

News

Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.

News

Trials of Lilly's Omvoh, Gilead's emvistegrast, Takeda's Entyvio, AbbVie's ABBV-466, and Sanofi/Teva's duvakitug are highlights of UEGW.

News

ViiV's long-acting injectable HIV drug, Cabenuva, has proved to be more effective than daily oral therapy for unsuppressed infections.

News

Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.

News

NICE's decision not to recommend NHS funding of Gilead's twice-yearly injectable for prevention of HIV has drawn fierce criticism from charities.

News

A new EC authorisation expands Gilead's market for triple-negative breast cancer ADC Trodelvy.